Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours
Mesenteric fibrosis (MF) surrounding a mesenteric mass is a hallmark feature of small intestinal neuroendocrine tumours (SI-NETs). Since this can induce intestinal obstruction, oedema and ischaemia, prophylactic resection of the primary tumour and mesenteric mass is often recommended. This study assessed the predictors for mesenteric metastasis and fibrosis and the effect of MF and palliative surgery on survival. A retrospective analysis of 559 patients with pathologically proven SI-NET and available CT-imaging data was performed. Clinical characteristics, presence of mesenteric mass and fibrosis on CT imaging and the effect of palliative abdominal surgery on overall survival were assessed. We found that MF was present in 41.4%. Older age, 5-HIAA excretion >67 μmol/24 h, serum CgA >121.5 μg/L and a mesenteric mass >27.5 mm were independent predictors of MF. In patients <52 years, mesenteric mass was less often found in women than in men (39% vs 64%, P = 0.002). Corrected for age, tumour grade, CgA and liver metastasis, MF was not a prognostic factor for overall survival. In patients undergoing palliative surgery, metastasectomy of mesenteric mass or prophylactic surgery did not result in survival benefit. In conclusion, we confirmed known predictors of MF and mesenteric mass and suggest a role for sex hormones as women <52 years have less often a mesenteric mass. Furthermore, the presence of MF has no effect on survival in a multivariate analysis, and we found no benefit of metastasectomy of mesenteric mass or prophylactic surgery on overall survival.
|Keywords||Fibrosis, Mesenteric mass, Neuroendocrine tumour, Prognosis, Surgery|
|Persistent URL||dx.doi.org/10.1530/ERC-17-0282, hdl.handle.net/1765/104993|
|Journal||Endocrine - Related Cancer|
Blažević, A, Zandee, W.T, Franssen, G, Hofland, J, van Velthuysen, M.L.F, Hofland, L.J, … de Herder, W.W. (2018). Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocrine - Related Cancer, 25(3), 245–254. doi:10.1530/ERC-17-0282